Mirati Therapeutics Executive Compensation (FY22)

Name: Mirati Therapeutics (MRTX) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

MRTX · Executive and director compensation, fiscal 2022 only

Chief executive, fiscal 2022

◇

David Meek

Median of the other named officers

$5,008,064

5 officers, excluding the chief executive

Velarion Member: every covered company in one industry, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The paid brief on Mirati Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$1,500 for the Executive Compensation Report. Both reports for $2,400.

Get the executive brief Get the board briefNo account needed.

Data as of October 17, 2026Latest filing (DEF 14A): April 6, 2023

1 filing cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Mirati Therapeutics brief$1,500Get the executive brief

Velarion Member, one year

127 figures on this page, cited to the filing that reported them. See the citations

Frequently asked questions

Answers drawn from the data on this page.

Who is Mirati Therapeutics' chief executive and what were they paid?

David Meek was paid $11,937,371 in total compensation as Chief Executive Officer for fiscal 2022.

Which companies are in Mirati Therapeutics' peer group?

The disclosed peer group includes ACADIA Pharmaceuticals, Agios Pharmaceuticals, Amicus Therapeutics, Arena Pharmaceuticals and Arrowhead Pharmaceuticals, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
David Meek Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Charles Baum President, Founder, Head of R&D	◇	—	◇	◇	◇	—	◇	◇
Laurie Stelzer Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
James Christensen Chief Scientific Officer	◇	—	◇	◇	◇	—	◇	◇
Alan Sandler Chief Medical Officer	◇	—	◇	◇	—	—	—	◇
Vickie Reed Former Chief Accounting Officer Departed during or after this year	◇	—	◇	◇	—	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2022 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Charles Baum	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	1/13/2032
	Option	◇	—	◇	1/14/2031
	Option	◇	—	◇	1/2/2030
	Option	◇	—	◇	1/16/2029
David Meek	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	1/13/2032
	Option	◇	—	◇	9/21/2031
James Christensen	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Laurie Stelzer	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
Alan Sandler	RSU	◇	◇	—	—

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

Alan Sandler

Chief Medical Officer · Employment agreement

Severance multiple	◇
Severance base	◇

Charles Baum

President, Founder, Head of R&D · Employment agreement

Severance multiple

◇

David Meek

Chief Executive Officer · Employment agreement

Severance multiple

◇

James Christensen

Chief Scientific Officer · Employment agreement

Severance multiple	◇
Severance base	◇

Director compensation

What each non-employee director was paid.

Fiscal 2022

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Faheem Hasnain	◇	◇	◇	—	—	—	◇
Craig Johnson	◇	◇	◇	—	—	—	◇
Bruce L.A. Carter	◇	◇	◇	—	—	—	◇
Julie M. Cherrington	◇	◇	◇	—	—	—	◇
Maya Martinez-Davis	◇	◇	◇	—	—	—	◇
Shalini Sharp	◇	◇	◇	—	—	—	◇
Henry J. Fuchs	◇	◇	◇	—	—	—	◇
Aaron I. Davis	◇	◇	◇	—	—	—	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Board chair premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Equity is delivered as Rsus/Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2022

ACADIA Pharmaceuticals ACAD
Agios Pharmaceuticals AGIO
Amicus Therapeutics FOLD
Arena Pharmaceuticals symbol not shown
Arrowhead Pharmaceuticals ARWR
CRISPR Therapeutics CRSP
Denali Therapeutics DNLI
Fate Therapeutics FATE
Intellia Therapeutics NTLA
Nektar Therapeutics NKTR
NovoCure NVCR

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- David Meek (Chief Executive Officer), FY2022 total compensation $11,937,371 (base salary $749,423) [exec_comp, SEC accession 0001628280-23-011004, filed 2023-04-06]

What this page does not include

Everything above is a fact Mirati Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where Mirati Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $1,500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $1,500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $499

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

127 figures on this page, cited to the filing that reported them.

127 cited to the filing

Documents cited

DEF 14A, filed April 6, 2023
0001628280-23-011004
Potential Payments Upon Termination

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Mirati Therapeutics executive compensation, FY2022.” https://intel.velarion.ai/comp/MRTX (accessed 2026).

Short form: data: Velarion

The paid brief for Mirati Therapeutics

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$1,500 for the Executive Compensation Report. Both reports for $2,400.

Get the executive brief Get the board briefNo account needed.

1 filing cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/MRTX/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Mirati Therapeutics executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Mirati Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Peers Mirati Therapeutics discloses

The companies named in MRTX's own disclosed peer group.

ACADIA Pharmaceuticals Agios Pharmaceuticals Amicus Therapeutics Arrowhead Pharmaceuticals CRISPR Therapeutics Denali Therapeutics Fate Therapeutics Intellia Therapeutics Nektar Therapeutics NovoCure

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}

More on Mirati Therapeutics

Frequently asked questions

Executive compensation

Outstanding awards

Severance and change in control

Director compensation

Director fee schedule

Disclosed peer group

Velarion Pro: every company page, peer tools and exports, one seat

What this page does not include

Citations

Documents cited

The paid brief for Mirati Therapeutics

Peers Mirati Therapeutics discloses

Terms on this page